RxDoctor Payments Data

Christina Gomez, MD

Medical Oncology · Gilbert, AZNPI 1679580997

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,900 of the $6,833 with a category attached, or 71.7%. E.r. Squibb & Sons, L.L.C. accounts for 97.7% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $6,679, more than ten times the $107 reported in 2019. That places this record below the midpoint for medical oncology clinicians in AZ, where the typical reported total is $8,518.

$6,833in general payments, 2019–2025

Across 12 payments — averaging $569.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$7K
  • Lilly USA, LLC$95
  • Chiesi USA, Inc.$26
  • Pfizer$21
  • Seagen Inc.$12
$23,080in research payments, 2019–2025

Across 3 payments — averaging $7693.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$23K

What the payments were for

  • Consulting fees$4,90072%
  • Travel & lodging$1,69925%
  • Food & beverage$2223%
  • Education$120%

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,833 in reported general payments places this provider in the 45th percentile of 59 medical oncology providers in Arizona.

See all medical oncology providers in Arizona

Medicare billing

Part B allowed, 2024
$68,367
Medicare patients
171
Services billed
586

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XermeloTelotristat Etiprate12$115,548
CreonLipase/Protease/Amylase28$110,416
EliquisApixaban23$20,754
Octreotide Acetate13$7,618
Prochlorperazine Maleate84$1,700
Ondansetron Hcl81$1,414
Oxycodone Hcl27$550
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine23$533
Pantoprazole Sodium23$312
Lidocaine-PrilocaineLidocaine/Prilocaine26$297
Dexamethasone20$155
Gabapentin21$149
Potassium Chloride11$93
Tramadol Hcl11$41
Prednisone14$20

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$20,75423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 59 medical oncology providers in Arizona.

Other medical oncology in Gilbert

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →